Publié le
Abstract: Purpose Pathologic complete response (pCR) has prognostic importance and is frequently used as a primary end point, but doubts…
Publié le
Randomized controlled trials (RCTs), particularly in phase 3, are the preferred sources of evidence for drug approval and reimbursement decisions….
Publié le
Generalized Pairwise Comparisons – GPC Today’s session is focusing on an innovative statistical methodology called Generalized Pairwise Comparisons – or…
Publié le
Phase I/II study in cancer patients showcases eClinical effectiveness. An Article written by IDDI Published in Applied Clinical Trials, February…
Publié le
Join IDDI experts to get updated on efficacy assessment in early-phase trials and more! THURSDAY, FEBRUARY 3 – 9:00 –…
Publié le
Be updated on different types of Bayesian and frequentist designs that may be used for expansion cohorts in phase 1…
Publié le
This webinar was presented by Laurence Collette, MSc, PhD, Principal Statistician, Consulting Services at IDDI at the 5th Annual Next…
Publié le
Demystifying different types of Bayesian and frequentist designs that may be used for first-in-human or other types of phase I…
Publié le
Using the promising-zone approach can salvage an underpowered trial. Sample size Re-estimation (SSRE) is a relatively new concept, but, thanks…
Publié le
Vaiva Deltuvaite-Thomas, Research Statistician, IDDI and Prof. Tomasz Burzykowski, VP Research IDDI have just published an article on operational characteristics…
